Novartis raises blockbuster drug forecasts to $18 billion as it seeks to prove growth can last
The drugmaker cited strong demand for its blockbuster drugs as it upgraded peak sales forecasts for multiple sclerosis, leukemia, and cholesterol medicines.
PublisherCNBC
Categorymarkets
Published2026-11-19T09:57:53Z
Indexed5h ago
More from CNBC
- Kraken parent's acquisition of Tribe Capital flags new chapter in evolution of crypto exchanges5m ago
- Walmart hikes outlook as CEO tells CNBC retailer aims to keep prices low despite soaring fuel costs39m ago
- Trump bought Nvidia, Palantir, SpaceX in September as federal deals, White House ties grew55m ago
- Trump, Xi, Putin said they plan to boost oil production, revamp UN after trilateral talks3h ago
Latest in markets
- Walmart hikes outlook as CEO tells CNBC retailer aims to keep prices low despite soaring fuel costsCNBC · 39m ago
- Why Micron, Broadcom and other AI stocks have given up their gainsMarketWatch · 55m ago
- The surprising reason the U.S. economy is speeding up — and might have more room to runMarketWatch · 1h ago
- Elon Musk becomes the latest tech billionaire to make a peace offering to Democrats after the midtermsMarketWatch · 1h ago
- Forget data centers. The next great AI stocks are hiding in plain sight in these four sectors.MarketWatch · 2h ago
FinancePulse indexes headlines and short summaries from 20 institutional publishers. This page does not republish the full article — all rights belong to CNBC.